OECD principles on water governance in practice:an assessment of existing frameworks in Europe, Asia-Pacific, Africa and South America

Through the lens of the 12 OECD Principles on Water Governance, this article examines six water resources and water services frameworks in Europe, Asia-Pacific, Africa and South America to understand enhancing and constraining contextual factors. Qualitative and quantitative methods are used to analyze each framework against four criteria: alignment; implementation; on-ground results; and policy impact. Four main target areas are identified for improving water governance: policy coherence; financing; managing trade-offs; and ensuring integrity and transparency by all decision makers and stakeholders. Suggestions are presented to support practical implementation of the principles through better government action and stakeholder involvement.No Full Tex

Interaction of ENSO-driven Flood Variability and Anthropogenic Changes in Driving Channel Evolution: Corryong/ Nariel Creek, Australia

This is an Accepted Manuscript of an article published by Taylor & Francis in Australian Geographer on 03/09/2015, available online: 10.1080/00049182.2015.1048595Understanding the relative contributions of climatic and anthropogenic drivers of channel change are important to inform river management, especially in the context of environmental change. This global debate is especially pertinent in Australia as catchments have been severely altered since recent European settlement, and there is also strong evidence of cyclical climate variability controlling environmental systems. Corryong/Nariel Creek is an ideal setting to further study the interaction between climate and anthropogenic changes on channel evolution as it has experienced both significant periods of flood and drought, controlled by the El Niño Southern Oscillation (ENSO), and extensive anthropogenic changes. Since European settlement the floodplain has been completely cleared, the riparian zone almost entirely invaded by willows, and every reach of the channel has experienced some form of direct channel modification. Through the combined analysis of channel evolution, climate changes and anthropogenic history of the river it was found that both the ENSO-driven climate and anthropogenic drivers are significant, although at different scales of channel change. Significant straightening in response to land clearing in the early twentieth century occurred before any records of direct channel modifications. Following this, most river management works were in response to instabilities created in the clearing period, or to instabilities created by flooding triggering a new phase of instability in reaches which had already undergone stabilisation works. Overall, human activities triggered channel instability via land clearing, and management works since then generally exacerbated erosion during high flows that are driven by climate fluctuations. This research raises the interesting question of whether rivers in Australia have become more responsive to the ENSO cycle since the clearing of catchment and riparian vegetation, or whether the past response to climate variability was different

Evolving Discourses on Water Resource Management and Climate Change in the Equatorial Nile Basin

Transboundary water resources management in the Equatorial Nile Basin (EQNB) is a politically contested issue. There is a growing body of literature examining water-related discourses which identifies the ability of powerful actors and institutions to influence policy. Concern about the effects of future climate change has featured strongly in research on the Nile River for several decades. It is therefore timely to consider whether and how these concerns are reflected in regional policy documents and policy discourse. This study analyzes discourse framings of water resources management and climate change in policy documents (27, published between 2001 and 2013) and as elicited in interviews (38) with water managers in the EQNB. Three main discursive framings are identified which are present in the discourses on both subjects: a problem-oriented environmental risk frame and two solution-oriented frames, on governance and infrastructure development. Climate change discourse only emerges as a common topic around 2007. The framings found in the water resources management discourse and the climate change discourse are almost identical, suggesting that discursive framings were adopted from the former for use in the latter. We infer that the climate change discourse may have offered a less politically sensitive route to circumvent political sensitivities around water allocation and distribution between riparian countries in the EQNB. However, the climate change discourse does not offer a lasting solution to the more fundamental political dispute over water allocation. Moreover, in cases where the climate change discourse is subsumed within a water resources management discourse, there are dangers that it will not fully address the needs of effective adaptation

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Rural Water Commission of Victoria

Made available by the Northern Territory Library via the Publications (Legal Deposit) Act 2004 (NT).Date:1992-0

Fourth progress report : irrigation in Egypt and Italy : a memorandum for the members of the Royal Commission on Water Supply /

Also available in an electronic version via the Internet at: http://nla.gov.au/nla.ms-ms1540-10-351; MS pbk copy signed "Mrs Brookes. Walsh St. South Yarra".Irrigation in Egypt and Ital